Form 4: Halozyme Therapeutics CEO Helen Torley Reports Stock Option and Restricted Stock Unit Grants

CEO Helen Torley reports the acquisition of stock options and restricted stock units in Halozyme Therapeutics.

Summary

• On February 23, 2024, Helen Torley, the President and CEO of Halozyme Therapeutics, Inc., was granted an option to purchase 93,002 shares of common stock at an exercise price of $40.56.
• This option vests one-fourth on February 23, 2025, and then 1/48th monthly thereafter.
• Torley also received 89,744 restricted stock units (RSUs) on February 23, 2024.
• These RSUs vest one-fourth on each anniversary of the grant date, starting February 23, 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options and RSUs to the CEO aligns her interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation to align executive interests with shareholder value.

Stakeholder Impact

• The grants incentivize the CEO to increase shareholder value.
• Employees may be indirectly impacted by the CEO's performance.

Key Dates